Tomoko Ueda-Consolvo1, Atsushi Hayashi2, Mayumi Ozaki2, Tomoko Nakamura2, Takaaki Yagou2, Shinya Abe2. 1. Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. cutomoko@med.u-toyama.ac.jp. 2. Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Abstract
PURPOSE: To assess the correlation between endothelial dysfunction and frequency of antivascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (nAMD). METHODS: We examined 64 consecutive patients with nAMD who were evaluated for endothelial function by use of peripheral arterial tonometry (EndoPAT 2000; Itamar Medical, Caesarea, Israel) at Toyama University Hospital from January 2015. We tallied the number of anti-VEGF treatments between January 2014 and December 2015 and determined the correlation between the number of anti-VEGF injections and endothelial function expressed as the reactive hyperemia index (RHI). Multiple regression analysis was also performed to identify the independent predictors of a larger number of injections. RESULTS: The mean number of anti-VEGF injections was 8.2 ± 3.3. The mean lnRHI was 0.47 ± 0.17. The lnRHI correlated with the number of anti-VEGF injections (r = -0.56; P = 0.030). The multiple regression analysis revealed that endothelial function, neovascular subtypes, and treatment regimens were associated with the number of injections. CONCLUSIONS: Endothelial dysfunction may affect the efficacy of anti-VEGF therapy. Neovascular subtypes may also predict a larger number of injections.
PURPOSE: To assess the correlation between endothelial dysfunction and frequency of antivascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (nAMD). METHODS: We examined 64 consecutive patients with nAMD who were evaluated for endothelial function by use of peripheral arterial tonometry (EndoPAT 2000; Itamar Medical, Caesarea, Israel) at Toyama University Hospital from January 2015. We tallied the number of anti-VEGF treatments between January 2014 and December 2015 and determined the correlation between the number of anti-VEGF injections and endothelial function expressed as the reactive hyperemia index (RHI). Multiple regression analysis was also performed to identify the independent predictors of a larger number of injections. RESULTS: The mean number of anti-VEGF injections was 8.2 ± 3.3. The mean lnRHI was 0.47 ± 0.17. The lnRHI correlated with the number of anti-VEGF injections (r = -0.56; P = 0.030). The multiple regression analysis revealed that endothelial function, neovascular subtypes, and treatment regimens were associated with the number of injections. CONCLUSIONS: Endothelial dysfunction may affect the efficacy of anti-VEGF therapy. Neovascular subtypes may also predict a larger number of injections.
Authors: Ronen Rubinshtein; Jeffrey T Kuvin; Morgan Soffler; Ryan J Lennon; Shahar Lavi; Rebecca E Nelson; Geralyn M Pumper; Lilach O Lerman; Amir Lerman Journal: Eur Heart J Date: 2010-02-24 Impact factor: 29.983
Authors: Naomi M Hamburg; Michelle J Keyes; Martin G Larson; Ramachandran S Vasan; Renate Schnabel; Moira M Pryde; Gary F Mitchell; Jacob Sheffy; Joseph A Vita; Emelia J Benjamin Journal: Circulation Date: 2008-05-05 Impact factor: 29.690
Authors: Ruth E Hogg; Jayne V Woodside; Sarah E C M Gilchrist; Ryan Graydon; Astrid E Fletcher; Wing Chan; Angela Knox; Barry Cartmill; Usha Chakravarthy Journal: Ophthalmology Date: 2007-10-22 Impact factor: 12.079
Authors: Anjali R Shah; Steven Williams; Caroline R Baumal; Bernard Rosner; Jay S Duker; Johanna M Seddon Journal: Am J Ophthalmol Date: 2015-12-15 Impact factor: 5.258